What is liraglutide, and what do I ask?

What is liraglutide?

Liraglutide (Victoza, Saxenda) is a modified version of a hormone from the gut. That body signal is involved in blood sugar and appetite, as the Saxenda medicine information explains.

Liraglutide is the ingredient name. Victoza and Saxenda are different named products.

What separates diabetes and weight products?

In September 2026, Victoza’s medicine information covered type 2 diabetes, a disease involving high blood sugar, and certain heart-related uses in adults with diabetes.

The Saxenda medicine information covered weight care. The products have different approved uses.

The reason for the prescription belongs in the discussion, alongside the ingredient name.

Are liraglutide generics real?

The Food and Drug Administration uses the short name FDA. This agency in the U.S. checks medicines for approval.

A generic has FDA approval of its own and is another version of a brand-name medicine.

Yes. September 2026 FDA records included approved liraglutide generics for diabetes care and separate ones for weight care.

A generic in the diabetes group cannot simply replace a product in the weight-care group.

An approved generic is different from a compounded medicine, which lacks FDA approval.

What does a weight study show?

In the SCALE weight study, adults without diabetes taking liraglutide had an average loss of 8.4 kilograms over 56 weeks (about 18.5 pounds).

The placebo group lost 2.8 kilograms, about 6.2 pounds. Placebo was a comparison shot without the active medicine.

Novo Nordisk funded this study. Its results describe a study group, not a promise to an individual.

What needs attention before comparing options?

The Saxenda medicine information lists nausea, a sick stomach, and other stomach side effects.

The thyroid, found in the neck, is a gland that makes hormones. Hormones are signals in the body.

Saxenda’s boxed warning is FDA’s strongest kind of medicine warning. It describes thyroid tumors in rats and mice. Whether liraglutide causes these tumors in people is unknown.

MEN 2 is a rare illness that a child can inherit from a parent. Its full name describes tumors in body parts that make hormones. If a relative has this diagnosis, bring the name to your visit. If you are unsure which illness a relative had, ask the care professional to help check the family history.

The medicine information rules out use if you or a relative has had medullary thyroid cancer, a rare cancer of that gland. Having MEN 2 also rules out use.

September 2026 FDA supply records marked Saxenda for discontinuation in January 2027. That means its supply is planned to end.